Private Equity Healthcare Acquisitions – June 2026

In light of continued investor interest in healthcare and therisks associated with private equity ownership of healthcare companies, the Private Equity Stakeholder Project is tracking private equity-backed healthcare acquisitions. Below is a list of private equity healthcare buyouts, growth investments, and add-on acquisitions completed during June 2026.

See May 2026 acquisitions here.

In June we tracked 14 buyouts, 45 add-on acquisitions, and 26 growth/expansion investments.

Lifepoint acquired eight of ScionHealth’s community hospitals

ScionHealth announced on June 2, 2026 Lifepoint Health had completed the acquisition of eight of its community hospitals:

• Bolivar Medical Center – Cleveland, Mississippi
• Ennis Regional Medical Center – Ennis, Texas
• Livingston Regional Hospital – Livingston, Tennessee
• Logan Regional Medical Center – Logan, West Virginia
• Palestine Regional Medical Center – Palestine, Texas
• Parkview Regional Hospital – Mexia, Texas
• Joseph Regional Medical Center – Lewiston, Idaho
• Watertown Regional Medical Center – Watertown, Wisconsin

Both Lifepoint and ScionHealth are owned by private equity firm Apollo Global Management. ScionHealth was created and received these hospitals as part of Apollo’s merger of Lifepoint and Kindred Healthcare in 2021. In 2020 Lifepoint’s private equity owners pursued a significant acquisition of Kindred hospitals. To finance the deal, Apollo pulled cash from Lifepoint and created a new entity, ScionHealth, to house some of the facilities along with significant debt. Apollo paid the previous private equity owners $900 million for the Kindred hospitals and Lifepoint from one buyout fund to another, potentially generating hundreds of millions of dollars in carried interest and other performance fees for the private equity firm and its executives.

Now, five years later, ScionHealth sold eight community hospitals back to Lifepoint, stating that the hand off is part of a “broader effort by ScionHealth to strengthen the company’s capital structure, focus on core strategies, and enhance the long-term support of the hospitals and communities it serves.” The eight hospitals acquired by Lifepoint were acute care or rehabilitation hospitals. As a result of the transaction, ScionHealth kept all its long-term acute care hospitals and divested itself of many of its non-long-term acute care facilities.

Private equity acquired several infusion therapy companies

Infusion therapy Infusion therapy typically takes place in one of four types of sites: hospitals, physician offices, ambulatory infusion centers, or at home. While hospitals have been the primary site of infusion therapies in the past, and some types of therapies must be administered in hospitals, investors expect that hospitals will diminish their market share of infusion therapy in the future, with care providers and patients opting for lower cost and higher convenience options such as ambulatory infusion centers, physician offices, and in-home.

Investors note that the industry represents “an attractive investment opportunity” due to an aging population, a rise in chronic diseases, and an increase in new infusible medications and specialty drugs. Private equity has been a particularly active investor, completing all of the deals in 2024. In an August 2025 presentation, an investment bank argued that the regionally fragmented infusion therapy services industry makes it a prime opportunity for acquisitions and platform creation, increasing consolidation. Some economists worry that consolidation and reduction in competition may lead to lower quality and higher prices.

The 2025 presentation claimed that “Specialty (Chronic) Infusion offers a recurring revenue stream underpinned by low turnover in patients who suffer from immune and autoimmune disorders that never fully resolve. Acute Therapies primarily consist of generic drugs that produce high margins, upwards of ~70%.”

Introduced legislation in the House and Senate may make home infusion companies even more lucrative for private equity firms. The bills seek to clarify that infusion companies may bill Medicare and Medicaid up to 50 percent of ordinary costs for infusion treatments in a patient’s home, even if a nurse or skilled medical professional is not present. Additionally, the Centers for Medicare & Medicaid Services is proposing new Medicare coverage for certain infusion pumps, drugs, and supplies to be used at home. The new rule may create new reimbursement opportunities for home infusion providers, suppliers, and manufacturers of related products.

The following transactions took place in the infusion services sector in June:

• Soleo Health acquired BluHaven Management and its parent company, Realo Specialty Care Pharmacy. BluHaven offers infusion therapy services. Realo Specialty Care Pharmacy provides clinical support and care coordination for patients requiring specialty treatment, including in-home infusion services.
• Singlepoint Healthcare acquired Healix, which provides infusion treatment at physician-owned and ambulatory infusion centers across the US.
• IVX Health received an undisclosed amount of development capital from RPS Ventures.

Private equity continued its investments in clinical trial and clinical research companies

Private equity firms completed the following transactions in the clinical trial and clinical research industry in June:

• Atlas Clinical Research announced its merger with Alliance Clinical Network, two companies focusing on clinical trial recruitment and execution. The merged company will continue to be supported by private equity firms Amulet Capital Partners and BPOC.
• Curewell Capital– and CFT Capital Partners-backed Alliance for Multispecialty Research acquired ClinOhio Research Services, a multi-therapeutic clinical research site in Columbus, Ohio.
• THL Partners-backed Headlands Research acquired two clinical research sites in Sacramento and Lincoln, California.

In its report on healthcare private equity activity in the first half of 2026, LevinPro that private equity-backed clinical research platform companies expanded through add-on acquisitions, growing geographically and strengthening their trial networks. In November 2025, PESP covered private equity’s expansion into the clinical trial industry and found a similar pattern of private equity consolidation of clinical research sites and ethics review boards. The 2025 blog concluded stating:

“Cost-cutting tactics and incorrectly approved trials have real human impacts. Clinical trials help ensure potential new interventions are safe and effective. It is imperative that participant rights are protected and that research is conducted ethically, to protect clinical trial participants from risk and to prevent dangerous interventions from being approved and instituted. The integrity of clinical trials depends on maintaining public trust, protecting participants, and ensuring that science rather than short-term financial returns guides the pursuit of medical innovation.”